Markets have picked up the pace from yesterday’s session, but today’s performance remains mixed. At the time of this writing, the Dow was down slightly, even as the S&P 500 and NASDAQ managed to post modest gains. The lingering risk of a US government shutdown is likely contributing to the sagging momentum.
In today’s blog, we take a break from our daily Top Performers to take a look at a ratings change from one of the most highly rated analysts tracked by our system. NewsQuantified provides our users with constantly updated Win% ratings for major financial analyst groups.
When they make a prediction on a stock, our data helps investors evaluate the predictive quality of the price target. Our news analytics platform enables NQ users to consistently find profitable trades, while our Analyst Actions tracking offers real-time business intelligence from some of the top investment groups in the world.
Winning on an outstanding 71% of their price target changes recorded by the NewsQuantified system, BTIG certainly seems to possess some pentetrating market insights.
Today they upgraded their rating on OCUL, moving the stock from “neutral” to “buy.” Ocular Theraputix focuses on researching, developing, and commercializing treatments for eye disease, utilizing its proprietary “hydrogel platform technology.” Their stock, currently trading around $6.35, has been suffering a years long decline after peaking around $42 in 2015. A legal battle surrounding an NDA from a clinical trial further dogged the stock over the second half of 2017.
BTIG sees OCUL as a strong rebound opportunity as it repositions to launch a flagship treatment—Dextenza—which BTIG analysts believe could be worth over $100 million in annual sales by 2022.
Specifically, BTIG sees the new 6-month regulatory approval timetable laid out by OCUL management as quite realistic.
Investors appear to have taken note of BTIG’s analysis in short order, buying the stock on heavy volume. It is up over 15% on today’s session, all since we first updated our users of the upgrade.
Diverse Plays, Great Profits: All in a single news day.
Keep checking our blog for daily updates on lucrative new-based stock plays, analyst actions, and more!
We analyze news events ranging from clinical trials in the pharmaceutical industry to routine earnings releases to major geopolitical shakeups.
Or, if you’re ready to move beyond the blog and experience the power of hedge-fund caliber news analysis in a package that’s accessible to small investors, click here to sign up for a free training today. You’ll see how easy to use our platform really is—and how many profitable trades it can unlock
A powerful news analytics platform like NewsQuantified not only makes it easy to track the news, but to quickly compare news events with key financial information. We make it simple to find strong, diverse plays in any market environment.
How are you using the news to earn market-beating profits? How would you use the news if you had access to a real-time platform like NewsQuantified? Let us know in the comments below.